Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Viking Therapeutics, Inc. - Common Stock
(NQ:
VKTX
)
33.12
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Viking Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know.
↗
February 25, 2026
Eli Lilly has seen revenue and earnings soar in recent years.
Via
The Motley Fool
Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.
↗
February 23, 2026
Is this the best way to cash in on the weight-loss gold rush?
Via
The Motley Fool
Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial
February 23, 2026
The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a...
Via
MarketMinute
VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report
↗
February 03, 2026
Via
Stocktwits
Why Viking Therapeutics Stock Is Up More Than 9% Today
↗
February 23, 2026
A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow.
Via
The Motley Fool
Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head
February 23, 2026
Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing...
Via
MarketMinute
Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial
February 23, 2026
COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated...
Via
MarketMinute
Topics
Earnings
3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds
↗
February 23, 2026
Viking stock has plenty of room to run.
Via
The Motley Fool
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street
↗
February 19, 2026
These biotech companies have catalysts ahead.
Via
The Motley Fool
Is Viking Therapeutics Stock Really Going to $125?
↗
February 19, 2026
Never say never. There's certainly a mathematical path to that level, if the company navigates it correctly.
Via
The Motley Fool
The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth
February 17, 2026
In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion...
Via
MarketMinute
Topics
Earnings
Economy
2026 Could Be a Big Year for Viking Therapeutics. Time to Buy?
↗
February 17, 2026
Viking should have plenty of news to share with investors this year.
Via
The Motley Fool
The Great Rotation: Russell 2000 Rockets 18% as Cooling Inflation Sparks Historic Small-Cap Surge
February 13, 2026
The financial landscape shifted violently this week as the long-dormant Russell 2000 index (INDEXRUSSELL:RUT) staged a breathtaking 18% rally, marking its best single-week performance in decades....
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
Small Caps Roar: Russell 2000 Surges as Cooling Inflation Ignites Rate Cut Hopes
February 13, 2026
In a decisive shift for equity markets, the small-cap heavy Russell 2000 index outperformed its large-cap peers on Friday, February 13, 2026, as investors cheered a cooler-than-expected Consumer Price...
Via
MarketMinute
Topics
Bonds
ETFs
Economy
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout?
↗
February 12, 2026
The company ended 2025 with $706 million in cash, which it said is enough to fund ongoing Phase 3 trials and maintenance data readouts.
Via
Stocktwits
Viking Therapeutics Stock Soars: What's Driving The Momentum?
↗
February 12, 2026
Viking Therapeutics (NASDAQ:VKTX) stock is soaring on Thursday, extending the momentum it picked up in Wednesday's after‑hours session following the company's fourth‑quarter earnings release.
Via
Benzinga
Nasdaq, S&P 500 Futures Rise, Markets Await Jobless Claims: Why NVDA, META, NKTR, NVCR, AMAT, ASTS Are On Traders' Radar Today
↗
February 12, 2026
Via
Stocktwits
Topics
Stocks
Viking (VKTX) Q4 2025 Earnings Call Transcript
↗
February 11, 2026
Viking (VKTX) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Intellectual Property
Dow, S&P 500 Futures Climb As House Votes To Rescind Trump Tariffs: Why VKTX, NVCR, APP, CRM, QS Are Trending After-Hours
↗
February 11, 2026
Via
Stocktwits
Topics
Government
Stocks
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline
↗
February 11, 2026
The company shared optimistic timelines for advancing the clinical studies of both oral and subcutaneous VK2735 in obesity.
Via
Stocktwits
Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore
↗
February 11, 2026
This stock has been known to soar after good news.
Via
The Motley Fool
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
↗
February 10, 2026
Could these two companies be biotech giants in the making?
Via
The Motley Fool
Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains?
↗
February 10, 2026
The stock has climbed in the triple digits over the past three years.
Via
The Motley Fool
3 Things Investors Need to Know About the Healthcare Sector in 2026
↗
February 07, 2026
The most recent gold rush in weight loss drugs isn't done just yet.
Via
The Motley Fool
Topics
Economy
Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition
February 06, 2026
Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83...
Via
MarketMinute
Topics
Earnings
Economy
The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts
February 05, 2026
In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a...
Via
MarketMinute
Topics
Earnings
Economy
The Smartest Growth Stock to Buy With $30 Right Now
↗
February 03, 2026
This pre-revenue biopharmaceutical stock is a home run swing worth taking.
Via
The Motley Fool
2 Biotech Stocks Set to Rebound in 2026
↗
January 27, 2026
They could perhaps see sustained runs beyond this year.
Via
The Motley Fool
Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker?
↗
January 26, 2026
Both companies may succeed in this industry.
Via
The Motley Fool
3 Growth Stocks to Invest $1,000 in Right Now
↗
January 24, 2026
It comes as no surprise that all three of them are capitalizing on relatively new, but game-changing, developments.
Via
The Motley Fool
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.